The Life Sciences and Health Care industry group strives to support clients in addressing challenges that impact the industry. As the life sciences and health care industry continues to evolve, professionals from across Deloitte's global network engage with clients to develop innovative solutions to help them achieve their respective business missions and move closer to their vision for the future. Contact the LSHC group to learn more about Deloitte's global industry practice.
| Focus: The pharmaceutical innovation dilemma Pharma innovation is facing a fundamental productivity challenge. Investment in R&D has outpaced sales growth, but this has not increased output of new medicines. Execs are seeking greater transparency in R&D decision making. |
||
| |
The next phase: Opportunities in China's pharmaceuticals market This Deloitte China report focuses on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors. |
|
![]() |
Measuring the return from innovation: Is R&D earning its investment? R&D leaders in the life sciences industry are under continued pressure to justify the investment in R&D. Deloitte and Thomson Reuters collaborated in producing this annual review of R&D returns in life sciences. |
|
| CBI Pharma/Biotech Accounting & Reporting Congress 2012 Deloitte is proud to again serve as the Lead Summa sponsor for this prestigious conference for financial and accounting executives in the life sciences industry. |